Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1392)	3/10/2003 11:08:45 AM
From: Icebrg	Read Replies (1) of 3044

FDA Accepts for Review NDA Filing and Grants Priority Review for VELCADE(TM) (bortezomib) for Injection Monday March 10, 11:03 am ET # CAMBRIDGE, Mass., March 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced that the U.S. Food and Drug Administration (FDA) accepted for review and granted Priority Review designation of the Company's New Drug Application (NDA) for VELCADE for the treatment of relapsed and refractory multiple myeloma. Priority Review is granted by the FDA to an NDA for a new treatment that addresses an unmet medical need. The FDA expedites the approval process for such an NDA by reducing the target review period for the application from 10 months to six months. Acceptance of the filing means that FDA has made a threshold determination that the NDA is sufficiently complete to permit a substantive review.(Photo: "We believe that the acceptance of our NDA for review is another step in our ongoing commitment of working to get this important medicine to multiple myeloma patients," said Barry Greene, general manager, oncology at Millennium. "The Agency's decision to grant the application Priority Review status underscores the potential therapeutic benefit of VELCADE and represents a significant step toward the Company's global mission of developing novel treatments in areas of significant unmet medical need." The acceptance of this filing comes approximately six weeks after the Company filed marketing applications in both the U.S. and the European Union (EU). VELCADE was granted fast track status by the FDA in June 2002, and Millennium filed the NDA under the provisions of Subpart H Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses on January 21, 2003. The Agency for the Evaluation of Medicinal Products (EMEA) accepted the Marketing Authorization Application (MAA) for review on February 24, 2003. The NDA submission was based primarily upon the results of the phase II SUMMIT trial, a multi-center study of 202 patents with relapsed and refractory multiple myeloma which were presented in full at the December 2002 meeting of the American Society of Hematology (ASH). The data were submitted electronically as well as in the common technical document (CTD) format, which allowed for nearly simultaneous filings in the U.S. and the EU.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next